psoriasis

News

BMS' deucravacitinib psoriasis pill outperforms Amgen's Otez...

Bristol-Myers Squibb could be on the verge of a major coup in psoriasis after its deucravacitinib pill outperformed Amgen’s rival Otezla.

Views & Analysis

Holistic immunology: Supporting patients at every stage of t...

As part of our series from leaders at Janssen, the company’s Max Pahlow looks at how approaches

News

Phase 3 wins put Dermavant closer to filing Otezla rival tap...

Just two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could be a few months away from filing for approval of

News

UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasi...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to th

News

Doctor Checking Skin Of Patient With Magnifying Glass

Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in p...

Eli Lilly is a latecomer in the new generation of biologic therapies for psoriasis with its mirikizumab candidate, but a win in a head-to-head trial against Novartis’ big-selli

Views & Analysis